In late 2023, Apple received a small blow to its lucrative Christmas sales period thanks to the medical device manufacturer ...

Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

You’ll learn about measuring blood oxygen saturation (SpO2), how to take and view readings ... if a settlement is reached between Apple and Masimo. That looks unlikely at the time of writing ...

Masimo Corp. and Apple Inc. have filed dueling post-trial briefs in a California federal court, following a retrial over ...

Masimo traded as high as $178.84 and last traded at $178.84, with a volume of 28200 shares traded. The stock had previously closed at $174.65. Several other research firms have also commented on MASI.

with Masimo previously accusing Apple of poaching its employees and copying its pulse oximetry technology. Why It Matters: ...

Offers optional dual IBP, and EtCo 2 — Now with Masimo SET ® Pulse Oximetry! The fully-functional Waveline Touch features a 12.1" color TFT display with a touch-screen interface. It features ...

Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion ™ pulse oximetry, introduced in 1995, has been shown in ...